ePosters
Complex Regional Pain Syndrome Type 1 (CRPS-1) is a rare, chronic, and often disabling condition with no FDA-approved medicines.1 Per the FDA, precision medicine targets the right treatments to the right patients at the right time.2 With this goal in mind, we explored factors to define patients who may respond better to neridronate treatment. We hypothesized that warm CRPS-1 subtype features3, generally present early in disease, may be one factor that indicates benefit with neridronate.
Giovanni Adami, MD, PhD
Rheumatologist
University of Verona, United States
Amarita S. Randhawa, PharmD
VP, Medical Affairs
Ambros Therapeutics, Inc
New City, New York, United States
Jeffrey Botbyl, MS
President & Chief Executive Officer
Provonix, United States
Gail Cawkwell, MD, PhD
Chief Medical Officer
Ambros Therapeutics, Inc, United States
Stephen Bruehl, PhD
Professor
Vanderbilt University Medical Center, United States